Sandoz
Clinical trials sponsored by Sandoz, explained in plain language.
Global generic and biosimilar pharmaceuticals company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a cheaper copy of ocrevus work just as well for MS? Results expected Nov 2026 (estimated)
-
Could a cheaper keytruda copy work just as well for melanoma?
Disease control CompletedThis study compares a new biosimilar drug (GME751) to the standard immunotherapy Keytruda in 322 adults with stage II or III melanoma that has been surgically removed. The goal is to see if the biosimilar stays in the body and works as well as Keytruda in preventing the cancer fr…
Phase 1 • Sponsor: Sandoz • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Cheaper keytruda alternative tested in lung cancer trial
Disease control CompletedThis phase 3 trial tested GME751, a biosimilar (copy) of the immunotherapy drug Keytruda, against the original Keytruda in 218 adults with untreated advanced non-squamous lung cancer. The goal was to see if GME751 works as well and is as safe as Keytruda when combined with chemot…
Phase 3 • Sponsor: Sandoz • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC